FDA approves Osimertinib with chemotherapy for advanced NSCLC with EGFR mutations, based on FLAURA2 trial data.

Osimertinib, in combination with platinum-based chemotherapy, has received FDA approval for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations. The approval follows data from the phase 3 FLAURA2 trial. Further research will help identify optimal patient subgroups and establish overall survival benefits compared to osimertinib alone.